Flavopiridol is primarily used in cancer research and treatment development due to its ability to inhibit cyclin-dependent kinases (CDKs), which play a key role in cell cycle regulation. By blocking these enzymes, it can halt the uncontrolled division of cancer cells. It has been studied in clinical trials for various cancers, including leukemia, lymphoma, and solid tumors. Its application extends to combination therapies, where it enhances the effects of other anticancer drugs by sensitizing tumor cells to chemotherapy or radiation. Additionally, Flavopiridol shows potential in targeting transcriptional pathways in malignant cells, making it a valuable tool in molecularly targeted cancer therapy.